TRACON Pharmaceuticals Inc Stock, NASDAQ:TCON
4350 La Jolla Village Drive, Suite 800, San Diego, California 92122-1243
United States of America
Number of Employees: 18
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.